GlaxoSmithKline (GSK), based in London, is a global healthcare company engaged in the discovery, dev...
Myovant: Emerging Leader in Woman's Health
11/10/2017 5:00 am EST
Myovant (MYOV) is an emerging biotech leader focused on developing and commercializing innovative therapies for women’s health and endocrine diseases, notes John McCamant, biotech sector expert and editor of The Medical Technology Stock Letter.
Its lead drug development candidate, Relugolix, is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that rapidly lowers estrogen and progesterone in women and testosterone levels in men when administered once-daily.
In our view, the drug candidate has the potential to a best in class molecule with superior efficacy, an improved safety profile and more convenient oral dosing options.
The compound is currently being tested in three Phase III trials, two in woman’s health and one in prostate cancer.
One of the company’s key strengths is its experienced leadership team, highlighted by the demonstrated success of its CEO, Dr. Lynn Seely. Dr. Seely was Chief Medical Officer at Medivation (MDVN) from 2005-2015 and led the development of XTANDI.
Adding to her stellar resume, she is board-certified in internal medicine and endocrinology and metabolism, and completed a clinical fellowship in endocrinology and metabolism at UC San Diego.
In addition to Dr. Seely, the team includes Bryan Selby who spent nearly a decade at Medivation, most recently as SVP, Product Strategy, and Dr. Laura Williams, M.D., MPH who spent 18 years at Abbott (ABT) and AbbVie (ABBV) and served as R&D Group Project Leader in Women’s Health.
In our view, the company has an excellent combination of an attractive Phase III asset and an experienced management team assembled to maximize shareholder value through astute drug development. We are initiating coverage of Myovant as a buy.
Related Articles on HEALTHCARE
iShares S&P Global Healthcare (IXJ) is an exchange-traded fund that seeks to track the S&P G...
We initiated coverage on drug contract research company Icon PLC (ICLR) in May 2016; in 17 months, t...
After a rather quiet year in 2017, Alkermes (ALKS) is due for major clinical, regulatory and commerc...